Skip to main content
Premium Trial:

Request an Annual Quote

DxS: Jun 6, 2007

Premium
Manchester, UK-based DxS announced last week the launch of its K-RAS Mutation Detection Kit.
 
The company, in a statement, cited recently published data that suggests that in lung cancer patients K-RAS mutation status is a strong predictor of resistance to therapy with tyrosine kinase inhibitors, such as AstraZeneca’s Iressa and Roche/OSI Pharmaceuticals’ Tarceva.
 
“The DxS K-RAS mutation detection kit can be used to identify these patients,” DxS said. “The kit will also be used to provide valuable biomarker information to drug companies with novel therapies in development.”
 
The real-time PCR-based kit detects seven key mutations in the K-RAS gene. The assays can detect less than 1 percent of mutations in wild type genomic DNA and have a limit of detection of 10 copies or below.
 
“The unparalleled sensitivity of the technology means that the kit detects mutations frequently missed by sequencing methods,” the company said.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.